Doxorubicin cardiomyopathy in lung cancer patients

Tariq Siddiqui, Ikram A. Burney

Research output: Contribution to journalArticle

Abstract

Doxorubicin is cardiotoxic and its use must be monitored carefully. Incidence of refractory cardiac failure is shown to increase once the cumulative dose exeeds 450 mg/m2. However, significant decline of ejection fraction (EF) may occur even at lower dose levels. EF was monitored using Multigated Radionuclide Angiography (MUGA) scan of all consecutive lung cancer patients, treated with Doxorubicin based regimens. Thirteen of 82 patients showed a significant (more than 15%) decline of left ventricular EF. The dose of doxorubicin producing this decline ranged between 91-180 mg/m2. Actual decline in EF ranged between 16-45%. Only 5 of 13 patients developed symptoms attributable to the cardiac disease. Doxorubicin can alter EF significantly in lung cancer patients at levels well below which are considered 'safe'. The reason for massive decline in ejection fraction in these patients has been hypothesized.

Original languageEnglish
Pages (from-to)142-145
Number of pages4
JournalJournal of the Pakistan Medical Association
Volume48
Issue number5
Publication statusPublished - May 1998

Fingerprint

Cardiomyopathies
Doxorubicin
Lung Neoplasms
Radionuclide Angiography
Stroke Volume
Heart Diseases
Heart Failure
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Doxorubicin cardiomyopathy in lung cancer patients. / Siddiqui, Tariq; Burney, Ikram A.

In: Journal of the Pakistan Medical Association, Vol. 48, No. 5, 05.1998, p. 142-145.

Research output: Contribution to journalArticle

@article{b236c585fbbd48cc910138d65b92dfc7,
title = "Doxorubicin cardiomyopathy in lung cancer patients",
abstract = "Doxorubicin is cardiotoxic and its use must be monitored carefully. Incidence of refractory cardiac failure is shown to increase once the cumulative dose exeeds 450 mg/m2. However, significant decline of ejection fraction (EF) may occur even at lower dose levels. EF was monitored using Multigated Radionuclide Angiography (MUGA) scan of all consecutive lung cancer patients, treated with Doxorubicin based regimens. Thirteen of 82 patients showed a significant (more than 15{\%}) decline of left ventricular EF. The dose of doxorubicin producing this decline ranged between 91-180 mg/m2. Actual decline in EF ranged between 16-45{\%}. Only 5 of 13 patients developed symptoms attributable to the cardiac disease. Doxorubicin can alter EF significantly in lung cancer patients at levels well below which are considered 'safe'. The reason for massive decline in ejection fraction in these patients has been hypothesized.",
author = "Tariq Siddiqui and Burney, {Ikram A.}",
year = "1998",
month = "5",
language = "English",
volume = "48",
pages = "142--145",
journal = "JPMA. The Journal of the Pakistan Medical Association",
issn = "0030-9982",
publisher = "Pakistan Medical Association",
number = "5",

}

TY - JOUR

T1 - Doxorubicin cardiomyopathy in lung cancer patients

AU - Siddiqui, Tariq

AU - Burney, Ikram A.

PY - 1998/5

Y1 - 1998/5

N2 - Doxorubicin is cardiotoxic and its use must be monitored carefully. Incidence of refractory cardiac failure is shown to increase once the cumulative dose exeeds 450 mg/m2. However, significant decline of ejection fraction (EF) may occur even at lower dose levels. EF was monitored using Multigated Radionuclide Angiography (MUGA) scan of all consecutive lung cancer patients, treated with Doxorubicin based regimens. Thirteen of 82 patients showed a significant (more than 15%) decline of left ventricular EF. The dose of doxorubicin producing this decline ranged between 91-180 mg/m2. Actual decline in EF ranged between 16-45%. Only 5 of 13 patients developed symptoms attributable to the cardiac disease. Doxorubicin can alter EF significantly in lung cancer patients at levels well below which are considered 'safe'. The reason for massive decline in ejection fraction in these patients has been hypothesized.

AB - Doxorubicin is cardiotoxic and its use must be monitored carefully. Incidence of refractory cardiac failure is shown to increase once the cumulative dose exeeds 450 mg/m2. However, significant decline of ejection fraction (EF) may occur even at lower dose levels. EF was monitored using Multigated Radionuclide Angiography (MUGA) scan of all consecutive lung cancer patients, treated with Doxorubicin based regimens. Thirteen of 82 patients showed a significant (more than 15%) decline of left ventricular EF. The dose of doxorubicin producing this decline ranged between 91-180 mg/m2. Actual decline in EF ranged between 16-45%. Only 5 of 13 patients developed symptoms attributable to the cardiac disease. Doxorubicin can alter EF significantly in lung cancer patients at levels well below which are considered 'safe'. The reason for massive decline in ejection fraction in these patients has been hypothesized.

UR - http://www.scopus.com/inward/record.url?scp=0032063085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032063085&partnerID=8YFLogxK

M3 - Article

VL - 48

SP - 142

EP - 145

JO - JPMA. The Journal of the Pakistan Medical Association

JF - JPMA. The Journal of the Pakistan Medical Association

SN - 0030-9982

IS - 5

ER -